Laser treatment in diffuse diabetic macular oedema

Article

Establishing the pattern of management of diffuse diabetic macular oedema in England

The characteristics of diffuse edema are:3
A. Enhanced visibility of retinal capillary bed.
B. Leakages from extensive areas of capillary bed in the macular area.
C. Scarcity or even absence of hard exudates.
D. Cystoid changes.

Diffuse maculopathy is a difficult form of diabetic retinopathy to treat. ETDRS scatter laser photocoagulation has been accepted as the mainstay of therapy.4–6 Intraocular injections of crystalline steroid preparations (Triamcinolone) has been advocated for treatment of refractory clinically significant macular oedema (CSME) which has not responded to laser therapy.7–11

Methods

Paper questionnaires were sent by post to 300 consultant ophthalmologists that were randomly selected from approximately 100 hospitals in England.

Result

Of the 300 consultant ophthalmologists, 137 completed and returned the questionnaire. 32% described themselves as a retinal specialist, 31% as a general ophthalmologist with an interest in medical retina while 37% described themselves as an ophthalmologist with different subspecialties.

Clinical assessment of DME

The data collected showed that after biomicroscopic identification of diffuse DME, only 5% would always request fluorescein angiography, 30% would request it most of the time while 65 % of them would only request occasionally. 63% will request OCT most of the time and the rest 37% only request it occasionally,

Treatment of DME

The analysed data reveals that 91% of the participants would recommend, as the first choice, argon green grid laser, the remaining 9% would use other laser types

Only 52% would repeat the grid if vision deteriorated, while 37% would only repeat if vision remained stable and the edema persisted. The remaining 11% would require additional information before treating

Retreatment

When a decision was made to retreat, 86% would perform the procedure, a minimum of 3 months after the previous treatment, 9% after 2 months, while 5% were unclear,

Intravitreal injection was recommended if laser treatment failed to achieve its goal by 51% of the participants, while 49% would not recommend it. 57% of them have referred refractory oedema for vitrectomy but 43% have not considered vitrectomy for their patients with refractory oedema (even if other modalities of treatment have failed). 35% of those who refer for vitrectomy would do so if laser treatment failed while the remaining 65% would refer for vitrectomy if both laser and intravitreal treatments failed

Stopping Laser treatment

When our participant colleagues were asked when to give up laser treatment, 3% would perform one grid laser treatment, 49% would perform two grids, 36% would perform three grids. 12% did not adhere to a formal algorithm. 80% will request fluorescein if first grid failed.

Vision Criteria

In our survey, 73% of the participating ophthalmologists would treat diffuse diabetic oedema in an eye with vision of 6/60 or less, however, 27% would not recommend any treatment.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.